CNCE - Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4 2022
New Online Registration Required for Live Call to Ask Questions
Audio-Only Webcast Still Available on Concert’s Website
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a business update.
Please note that there is a new system to access the live call in order to ask questions. To join the live call, please register here. A dial in and unique PIN will be provided to join the call.
An audio-only webcast of the call may be accessed in the Investors section of the Company’s website at www.concertpharma.com . A replay of the webcast will be available on Concert’s website for three months.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform ® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220729005197/en/
For additional information contact:
Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com